ClinicalTrials.gg
RecruitingNCT07877818Updated Nov 6, 2026

A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.

A Phase 3 interventional study of FLOT Chemotherapy and Durvalumab in Gastric and Esophagogastric Junction, sponsored by AstraZeneca. Recruiting at 41 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 6, 2026Now RecruitingFirst site in China+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to assess the efficacy and safety of neoadjuvant adjuvant treatment with durvalumab in combination with FLOT compared to placebo in combination with FLOT in Chinese patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN-CN).

Read the detailed description

Informed by the favorable benefit-risk profile demonstrated by the global MATTERHORN study, the current study is designed to assess the efficacy and safety of neoadjuvant-adjuvant durvalumab in combination with FLOT chemotherapy followed by adjuvant durvalumab monotherapy (Arm A), compared with neoadjuvant-adjuvant placebo in combination with FLOT chemotherapy followed by adjuvant placebo monotherapy (Arm B) in Chinese participants with resectable GC/GEJC. Approximately 140 participants will be randomized to either Arm A or Arm B.

02

Conditions studied

  • Gastric
  • Esophagogastric Junction

Keywords

  • Durvalumab
  • FLOT chemotherapy
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Capable of giving signed . 2. Male and/or Female, Age ≥ 18 years at the time of screening. 3. documented gastric or gastroesophageal junction adenocarcinoma with resectable disease, GEJC includes Siewert* type 2 and 3 tumour and Siewert* type 1 tumour.

    1. Per the judgment of the Investigator, participants must be medically fit for treatment with FLOT therapy prior to radical surgery.
    2. At screening, complete surgical resection of the primary GC/GEJC must be deemed achievable, as assessed by a multidisciplinary evaluation, which must include a board certified GI surgeon.
    3. No prior anti-cancer therapy (eg, chemotherapy, radiation therapy, or chemoradiation therapy) for the current .

      4. PS of 0 or 1 with no deterioration over the previous 2 weeks prior to baseline at screening and prior to randomization.

      5. Adequate organ and marrow function as defined below:

    <!-- -->

    1. ≥ 9.0 g/dL
    2. ≥ 1.5 × 109/L
    3. count ≥ 100 × 109/L
    4. Serum ≤ 1.5 ×. This will not apply to participants with confirmed Gilbert's syndrome, who will be allowed in consultation with their physician.
    5. and AST ≤ 2.5 × ULN
    6. Measured CL > 50 mL/min or Calculated CL > 50 mL/min as determined by (using actual body weight) 6. Must have a of at least 24 weeks. 7. Body weight > 30 kg at enrolment and randomization. 8. Meeting tumour sample requirements (at screening) to confirm status.

Exclusion criteria

Exclusion Criteria:

  • -1. Participants with peritoneal dissemination (including tumour cells in peritoneal fluid) or distant .

    2. Participants with adenosquamous cell carcinoma, squamous cell carcinoma, or GI stromal tumour.

    3. History of allogeneic organ transplantation. 4. Active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], systemic lupus erythematosus, sarcoidosis, granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc), autoimmune pneumonitis, and autoimmune myocarditis.

    5. Uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written .

    6. History of another primary except for

    (a) Malignancy treated with curative intent and with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence (b) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease (c) Adequately treated carcinoma in situ without evidence of disease 7. History of active primary immunodeficiency. 8. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice) and verified by positive HIV-1 or HIV-2 antibodies.

    9. Mean ≥ 470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart).

    10. Known allergy or to any of the study interventions or any of the study intervention .

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Arm A

    Durvalumab +FLOT followed by durvalumab

    Drug: FLOT Chemotherapy · Drug: Durvalumab

  • Placebo comparator
    Arm B

    Placebo +FLOT followed by Placebo

    Drug: FLOT Chemotherapy

Interventions

06

What researchers measure

Primary outcomes

  1. To compare Arm A relative to Arm B on pCR rate

    pCR rate is defined as the proportion of participants who have no residual viable tumour in the resected specimens and as determined by central pathology review.

    Time frame: Up to 24 months after the last participant is randomized

Secondary outcomes

  1. To compare Arm A relative to Arm B on event-free survival at 24 months (EFS24)

    EFS24 is the proportion of participants alive and event free 24 months after randomization, according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 per Investigator assessment and/or locally by pathology testing.

    Time frame: Up to 24 months after the last participant is randomized

  2. To compare Arm A relative to Arm B on overall survival (OS)

    Overall survival is length of time from randomization until the date of death due to any cause.

    Time frame: Up to 24 months after the last participant is randomized

  3. To compare Arm A relative to Arm B on event-free survival (EFS)

    EFS is defined as the time from randomization to the following, according to RECIST 1.1 per Investigator assessment and/or locally by pathology testing: 1. Progression that precludes surgery or requires non-protocol therapy, 2. Local or distant recurrence or progression of disease, or 3) Death due to any cause.

    Time frame: Up to 24 months after the last participant is randomized

  4. To compare Arm A relative to Arm B on the rate of complete resection (R0)

    R0 resection (complete resection) rate is the proportion of participants who have a confirmed complete resection as assessed by pathology review.

    Time frame: Up to 24 months after the last participant is randomized

  5. To compare Arm A relative to Arm B on metastasis-free survival (MFS) and disease-specific survival (DSS)

    MFS is the time from randomization until the development of metastasis using RECIST 1.1 or death due to any cause. • DSS is the time from randomization untildeath due to GC/GEJC.

    Time frame: Up to 24 months after the last participant is randomized

  6. To compare Arm A relative to Arm B on disease-free survival (DFS) in participants who undergo R0 resection surgery

    DFS is defined as the time from first post-surgery scan until disease recurrence, using RECIST 1.1, or death due to any cause.

    Time frame: Up to 24 months after the last participant is randomized

Other outcomes

  1. To assess the safety and tolerability of Arm A as compared to Arm B in participants with GC/GEJC

    Safety and tolerability will be evaluated in terms of adverse events (AEs)

    Time frame: Up to 24 months after the last participant is randomized

07

Study locations

11 of 41 sites recruiting
  • Research Site
    Beijing, 100050, China
    Not yet recruiting
  • Research Site
    Beijing, 100142, China
    Recruiting
  • Research Site
    Beijing, 100730, China
    Not yet recruiting
  • Research Site
    Beijing, 102206, China
    Not yet recruiting
  • Research Site
    Beijing, 102218, China
    Not yet recruiting
  • Research Site
    Bengbu, 233004, China
    Not yet recruiting
  • Research Site
    Changchun, 130021, China
    Not yet recruiting
  • Research Site
    Changchun, 130033, China
    Recruiting
  • Research Site
    Changsha, 410008, China
    Not yet recruiting
  • Research Site
    Changzhi, 046000, China
    Not yet recruiting
  • Research Site
    Chengdu, 610041, China
    Not yet recruiting
  • Research Site
    Chengdu, 610041, China
    Recruiting
  • Research Site
    Chongqing, 400042, China
    Not yet recruiting
  • Research Site
    Fuzhou, 350001, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510080, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510120, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510655, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310014, China
    Recruiting
  • Research Site
    Hangzhou, 310016, China
    Not yet recruiting
  • Research Site
    Hohhot, 010020, China
    Not yet recruiting
  • Research Site
    Jinan, 250014, China
    Recruiting
  • Research Site
    Jinan, 250021, China
    Not yet recruiting
  • Research Site
    Kunming, 650118, China
    Not yet recruiting
  • Research Site
    Lanzhou, 730000, China
    Recruiting
  • Research Site
    Lanzhou, 730030, China
    Not yet recruiting
  • Research Site
    Meizhou, 514031, China
    Recruiting
  • Research Site
    Nanchang, 330006, China
    Not yet recruiting
  • Research Site
    Nanjing, 210009, China
    Not yet recruiting
  • Research Site
    Nanjing, 210029, China
    Not yet recruiting
  • Research Site
    Nanning, 530021, China
    Not yet recruiting
  • Research Site
    Qingdao, 266003, China
    Recruiting
  • Research Site
    Shanghai, 200031, China
    Not yet recruiting
  • Research Site
    Shanghai, 200032, China
    Not yet recruiting
  • Research Site
    Shanghai, 201210, China
    Not yet recruiting
  • Research Site
    Shaoguan, 512027, China
    Recruiting
  • Research Site
    Shenyang, 110042, China
    Not yet recruiting
  • Research Site
    Suining Shi, 629000, China
    Recruiting
  • Research Site
    Taiyuan, 030000, China
    Not yet recruiting
  • Research Site
    Wuhan, 430030, China
    Not yet recruiting
  • Research Site
    Xi'an, 710068, China
    Recruiting
  • Research Site
    Zhengzhou, 450000, China
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD will be sharedQualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared. upon certain conditions.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Nov 2029, 36 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Oct 16, 2026
StartActual
Oct 9, 2026was Nov 2026
Primary completionEst.
Nov 1, 2029
CompletionEst.
Nov 1, 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
41 sites added — first site in China
Show 41 added (41 China)
  • Research Site · Beijing, China
  • Research Site · Beijing, China
  • Research Site · Beijing, China
  • Research Site · Beijing, China
  • Research Site · Beijing, China
  • Research Site · Bengbu, China
  • Research Site · Changchun, China
  • Research Site · Changchun, China
  • Research Site · Changsha, China
  • Research Site · Changzhi, China
  • Research Site · Chengdu, China
  • Research Site · Chengdu, China
  • Research Site · Chongqing, China
  • Research Site · Fuzhou, China
  • Research Site · Guangzhou, China
  • Research Site · Guangzhou, China
  • Research Site · Guangzhou, China
  • Research Site · Hangzhou, China
  • Research Site · Hangzhou, China
  • Research Site · Hohhot, China
  • Research Site · Jinan, China
  • Research Site · Jinan, China
  • Research Site · Kunming, China
  • Research Site · Lanzhou, China
  • Research Site · Lanzhou, China
  • Research Site · Meizhou, China
  • Research Site · Nanchang, China
  • Research Site · Nanjing, China
  • Research Site · Nanjing, China
  • Research Site · Nanning, China
  • …and 11 more on the registry record
Nov 6, 2026
Start date
Nov 30, 2026→Oct 9, 2026 (actual)
Nov 6, 2026
Registered
First appeared on the registry
Oct 16, 2026
Show all 2 updates
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    41 sites added — first site in China
    Show 41 added (41 China)
    • Research Site · Beijing, China
    • Research Site · Beijing, China
    • Research Site · Beijing, China
    • Research Site · Beijing, China
    • Research Site · Beijing, China
    • Research Site · Bengbu, China
    • Research Site · Changchun, China
    • Research Site · Changchun, China
    • Research Site · Changsha, China
    • Research Site · Changzhi, China
    • Research Site · Chengdu, China
    • Research Site · Chengdu, China
    • Research Site · Chongqing, China
    • Research Site · Fuzhou, China
    • Research Site · Guangzhou, China
    • Research Site · Guangzhou, China
    • Research Site · Guangzhou, China
    • Research Site · Hangzhou, China
    • Research Site · Hangzhou, China
    • Research Site · Hohhot, China
    • Research Site · Jinan, China
    • Research Site · Jinan, China
    • Research Site · Kunming, China
    • Research Site · Lanzhou, China
    • Research Site · Lanzhou, China
    • Research Site · Meizhou, China
    • Research Site · Nanchang, China
    • Research Site · Nanjing, China
    • Research Site · Nanjing, China
    • Research Site · Nanning, China
    • …and 11 more on the registry record
    Start date Nov 30, 2026→Oct 9, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07877818
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 16, 2026
Start date
Oct 9, 2026
Primary completion
Nov 1, 2029 (estimated)
Completion
Nov 1, 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion